BSECompany Update3h ago · 22 Jul 2026, 04:22 pm
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company, as a ....
Jagsonpal Pharmaceuticals Ltd · 507789
✦ AI SummaryResults
Jagsonpal Pharmaceuticals Ltd has scheduled a conference call with analysts/investors on July 30, 2026, to discuss its Q1 FY27 financial results.
Analysis Scores
Earnings Impact8/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
fee46202-0b8f-4e3c-9098-e8ec5dc4ca50.pdf
View document text
Jagsonpal Pharmaceuticals Ltd
( ::.:&.mu •
-~ Sakht
Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)
Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative
lJAGSONPAL!
CIN. : L74899DL1978PLC009181
July 22, 2026
The Department of Corporate Services- Listing The Department of Corporate Services- Listing
BSE Ltd, National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G,
Dalal Street Bandra Kurla Complex,
Mumbai-400 001 Bandra (E) Mumbai – 400 051
Scrip Code: 507789 Symbol: JAGSNPHARM
Subject: Intimation of Analysts/ Investors Conference call
Dear Sir/ Madam,
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, we wish to inform you that the Company, as a part of its investors engagement
activities, has scheduled a conference call with the Analysts / Investors on Thursday, July 30, 2026, to discuss its
Q1 FY27 financial results. The Conference call details is attached as Annexure.
We request you to take the above on record.
Thanking you,
Yours faithfully,
For Jagsonpal Pharmaceuticals Limited
Pratham Rawal
Company Secretary & Compliance Officer
Encl.: A/a
Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)
Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070
Go India Advisors
JAGSONPAL
Jagsonpal Pharmaceuticals Limited
Q1FY27 Earnings Conference Call
Hosted by Go India Advisors
Company Participants
Thursday, 30th July 2026 IST 2:30 PM
Call in Details:
Pre-register to avoid wait time, join with Diamond Pass.
Registration link: CLICK HERE
Dial in Numbers: Please dial-in at least 5-10 minutes prior
to the conference call schedule to ensure that you are
connected to the call on time
Universal Dial-In Numbers
+91 22 6280 1557 / +91 22 7115 8383
For further information, kindly contact:
Soumya Chhajed Sheetal Khanduja
soumya@goindiaadvisors.com sheetal@goindiaadvisors.com